Tonghua Dongbao Pharmaceutical (600867.SH): Summary Report of Phase Ib Clinical Trial of Injection THDBH120 for Reducing Blood Sugar Indications.

Tonghua Dongbao Pharmaceutical (600867.SH) announced that its wholly-owned subsidiary, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (referred to as "Dongbao Zixing"), has completed a key Phase Ib clinical trial ("a randomized, double-blind, placebo-controlled Phase Ib clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of injection THDBH120 in Chinese adult type 2 diabetes patients") and has received the summary report of the clinical trial. The research results show that the main endpoint goal has been achieved.